<!DOCTYPE HTML>
<html>
  <head>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8">
    <title>Lithium</title>
	</head>
  <body onload="init();">
    <div data-role="page" data-theme="b">
  	<div data-role="header" data-theme="b" data-position="inline">
    	<h1>Lithium</h1> 
    	<a href="#" data-rel="back" data-icon="arrow-l" data-theme="b" data-direction="reverse" >Back</a>
	</div>
    <div data-role="content">
<ul data-role="listview" data-inset="true" >
		<li><a href="brands/lithium.html" >Lithium</a></li>	
		<li><a href="brands/lithium_er.html" >Lithium ER (Lithobid)</a></li>	
	</ul>	
	
	<a href="pro_con.html"data-role="button" data-icon="arrow-r" data-iconpos="right">Pros and Cons</a>
	<a href="monitor_referrals_warn.html" data-role="button" data-icon="arrow-r" data-iconpos="right">Monitoring, Referrals and Warnings</a>
	<a href="blackbox.html" data-theme="a" data-role="button" data-icon="arrow-r" data-iconpos="right">Black Box Warning</a>
	</div>
	    <div data-role="content">
  	<p>Use with caution in thyroid disease, mild-moderate cardiovascular disease, mild-moderate renal disease, patients with significant fluid loss, patients at risk of suicide and the elderly.</p>
   		<p>Avoid use in the mTBI patient. Patients currently taking lithium may develop a neurotoxic syndrome marked by increased mental confusion, disorientation, and unresponsiveness when used with electroconvulsive therapy.</p>
   		<p>Lithium has been studied as augmentation in MDD for first-line medications and Tricyclic Antidepressants. Bupropion SR and buspirone are recommended as initial choices for augmentation since their efficacy has been demonstrated in at least one randomized clinical trial and their safety and tolerability profiles are more favorable than lithium.</p>
      </div>
 
    </div><!-- end jqm content -->
   

  </body>
</html>
